HRP20010566A2 - (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same - Google Patents

(1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same Download PDF

Info

Publication number
HRP20010566A2
HRP20010566A2 HR20010566A HRP20010566A HRP20010566A2 HR P20010566 A2 HRP20010566 A2 HR P20010566A2 HR 20010566 A HR20010566 A HR 20010566A HR P20010566 A HRP20010566 A HR P20010566A HR P20010566 A2 HRP20010566 A2 HR P20010566A2
Authority
HR
Croatia
Prior art keywords
formula
compound
image
salts
represented
Prior art date
Application number
HR20010566A
Other languages
English (en)
Croatian (hr)
Inventor
Jean Philippe Ducoux
Xavier Edmonds-Alt
Patrick Gueule
Vincenzo Proietto
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9901593A external-priority patent/FR2789389B3/fr
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of HRP20010566A2 publication Critical patent/HRP20010566A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20010566A 1999-02-10 2000-02-08 (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same HRP20010566A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9901593A FR2789389B3 (fr) 1999-02-10 1999-02-10 Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
FR9904429A FR2789390B3 (fr) 1999-02-10 1999-04-07 Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
PCT/FR2000/000284 WO2000047572A1 (fr) 1999-02-10 2000-02-08 Derives de (1-phenacy-3-phenyl-3-piperidylethyl)piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
HRP20010566A2 true HRP20010566A2 (en) 2002-08-31

Family

ID=26234812

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010566A HRP20010566A2 (en) 1999-02-10 2000-02-08 (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same

Country Status (36)

Country Link
US (2) US6642233B1 (cs)
EP (1) EP1150970B1 (cs)
JP (1) JP4648544B2 (cs)
KR (1) KR100611261B1 (cs)
CN (1) CN1273463C (cs)
AR (1) AR028813A1 (cs)
AT (1) ATE370942T1 (cs)
AU (1) AU763716B2 (cs)
BG (1) BG65031B1 (cs)
BR (1) BR0008067A (cs)
CA (1) CA2360894C (cs)
CO (1) CO4980896A1 (cs)
CZ (1) CZ300765B6 (cs)
DE (1) DE60036081T2 (cs)
DK (1) DK1150970T3 (cs)
EE (1) EE04437B1 (cs)
ES (1) ES2291187T3 (cs)
FR (1) FR2789390B3 (cs)
HR (1) HRP20010566A2 (cs)
HU (1) HUP0201281A3 (cs)
ID (1) ID29219A (cs)
IL (2) IL144363A0 (cs)
ME (1) MEP11908A (cs)
NO (2) NO321149B1 (cs)
NZ (1) NZ513053A (cs)
PE (1) PE20001463A1 (cs)
PL (1) PL198561B1 (cs)
PT (1) PT1150970E (cs)
RS (1) RS50210B (cs)
RU (1) RU2220956C2 (cs)
SI (1) SI1150970T1 (cs)
SK (1) SK286401B6 (cs)
TR (1) TR200102331T2 (cs)
TW (1) TWI254712B (cs)
UA (1) UA70986C2 (cs)
WO (1) WO2000047572A1 (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009798A1 (en) * 2002-02-20 2005-01-13 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
WO2003070745A2 (en) * 2002-02-20 2003-08-28 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids
EP1713506A1 (en) * 2004-01-30 2006-10-25 Pfizer Products Incorporated Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration
FR2873373B1 (fr) * 2004-07-23 2006-09-08 Sanofi Synthelabo Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique
GB2452696B (en) * 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
DE102008015425A1 (de) * 2008-03-20 2010-01-21 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen zur Verringerung von Juckreiz und anderen dermatologischen Missempfindungen, die insbesondere bei Altershaut auftreten können, mit einem Gehalt an (1R,2S,5R)-2-Isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl-cyclohexancarboxamid und/oder (1R,2S,5R)-N-(4-(Cyanomethyl)-phenyl)-2-isopropyl-5-methylcyclohexancarboxamid
DE102008015428A1 (de) * 2008-03-20 2009-09-24 Beiersdorf Ag Kühlende Zubereitungen für den humanen Haut- und/oder Schleimhautkontakt mit einem Gehalt an (1R,2S,5R)-2-Isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl-cyclohexancarboxamid und/oder (1R,2S,5R)-N-(4-(Cyanomethyl)-phenyl)-2-isopropyl-5-methylcyclohexancarboxamid
DE102008015426A1 (de) * 2008-03-20 2009-09-24 Beiersdorf Ag Kühlende kosmetische oder dermatologische Zubereitungen mit einem Gehalt an (1R,2S,5R)-2-Isopropyl-5-methyl-N-(2-(pyridyn-2-yl)ethyl-cyclohexancarboxamid und/oder (1R,2S,5R)-N-(4-(Cyanomethyl)-phenyl)-2-isopropyl-5-methylcyclohexancarboxamid zu Reduktion von Hautrötungen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US512901A (en) * 1894-01-16 Folding bed
GB821012A (en) * 1957-01-15 1959-09-30 Rhone Poulenc Sa New phenthiazine derivatives and processes for their preparation
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
MX9701305A (es) * 1994-08-25 1998-05-31 Merrell Pharma Inc Piperidinas sustituidas novedosas utiles para el tratamiento de enfermedades alergicas.
EP0714891A1 (en) * 1994-11-22 1996-06-05 Eli Lilly And Company Heterocyclic tachykinin receptor antagonists

Also Published As

Publication number Publication date
UA70986C2 (uk) 2004-11-15
SK11392001A3 (sk) 2002-02-05
ATE370942T1 (de) 2007-09-15
HUP0201281A3 (en) 2003-05-28
AU2553100A (en) 2000-08-29
JP4648544B2 (ja) 2011-03-09
CO4980896A1 (es) 2000-11-27
SI1150970T1 (sl) 2008-02-29
SK286401B6 (sk) 2008-09-05
DE60036081D1 (de) 2007-10-04
PE20001463A1 (es) 2001-02-21
NO20013878D0 (no) 2001-08-08
IL144363A0 (en) 2002-05-23
HUP0201281A2 (en) 2002-09-28
EE200100417A (et) 2002-12-16
CZ300765B6 (cs) 2009-08-05
US6642233B1 (en) 2003-11-04
DE60036081T2 (de) 2008-05-15
CA2360894A1 (en) 2000-08-17
US6951940B2 (en) 2005-10-04
EP1150970B1 (fr) 2007-08-22
BG65031B1 (bg) 2006-12-29
AU763716B2 (en) 2003-07-31
CZ20012888A3 (cs) 2001-11-14
EP1150970A1 (fr) 2001-11-07
BG105794A (en) 2002-05-31
CA2360894C (en) 2009-09-22
BR0008067A (pt) 2001-11-06
YU56401A (sh) 2004-03-12
MEP11908A (en) 2010-06-10
US20040072840A1 (en) 2004-04-15
CN1273463C (zh) 2006-09-06
HK1038927A1 (en) 2002-04-04
RU2220956C2 (ru) 2004-01-10
KR20010101818A (ko) 2001-11-14
JP2002536442A (ja) 2002-10-29
DK1150970T3 (da) 2007-12-17
NO20013878L (no) 2001-10-10
AR028813A1 (es) 2003-05-28
TWI254712B (en) 2006-05-11
WO2000047572A1 (fr) 2000-08-17
CN1345317A (zh) 2002-04-17
ES2291187T3 (es) 2008-03-01
PL198561B1 (pl) 2008-06-30
NZ513053A (en) 2002-10-25
PT1150970E (pt) 2007-11-07
TR200102331T2 (tr) 2002-03-21
RS50210B (sr) 2009-07-15
NO321149B1 (no) 2006-03-27
PL350243A1 (en) 2002-12-02
KR100611261B1 (ko) 2006-08-10
ID29219A (id) 2001-08-16
EE04437B1 (et) 2005-02-15
IL180579A0 (en) 2007-06-03
NO20051958L (no) 2001-10-10
FR2789390A1 (fr) 2000-08-11
FR2789390B3 (fr) 2001-03-09

Similar Documents

Publication Publication Date Title
HRP20010566A2 (en) (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same
TWI258480B (en) Novel piperidinecarboxamide derivatives, a method for their preparation and pharmaceutical compositions containing them
US6506750B1 (en) Morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives
KR100611262B1 (ko) (1-페나시-3-페닐-3-피페리딜에틸)피페리딘 유도체, 그의제조 방법 및 이를 함유하는 제약 조성물
FR2789389A1 (fr) Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
MXPA01008119A (en) (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same
HK1038927B (en) (1-phenacy-3-phenyl-3-piperidylethyl) piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: SANOFI-AVENTIS, FR

ODRP Renewal fee for the maintenance of a patent

Payment date: 20100208

Year of fee payment: 11

ODBC Application rejected